Drug launch by Lupin - Tacrolimus Capsules - Angel Broking

Mr. Yash Gupta - Equity Research Associate, Angel Broking Ltd

"Lupin limited up by 1% at 902 on positive news of the launch of Tacrolimus Capsules. Lupin Limited announced the launch of Tacrolimus Capsules USP after Lupin's alliance partner Concord Biotech Limited received an approval for its ANDA from the United States Food and Drug Administration (U.S. FDA). Tacrolimus Capsules USP, 0.5 mg, 1 mg, and 5 mg, are the generic equivalent of Prograf® Capsules, of Astellas Pharma US, Inc. and are indicated for the prophylaxis of organ rejection, in adult patients receiving allogeneic kidney transplant, liver transplant, and heart transplant, and in pediatric patients receiving allogeneic liver transplants, in combination with other immunosuppressants. Tacrolimus Capsules USP had an annual sale of approximately USD 303 million in the U.S. as per IQVIA MAT September 2020 data."

Shares of LUPIN LTD. was last trading in BSE at Rs.894.55 as compared to the previous close of Rs. 895.2. The total number of shares traded during the day was 112124 in over 3884 trades.

The stock hit an intraday high of Rs. 907.65 and intraday low of 889. The net turnover during the day was Rs. 100641796.

Source : Equity Bulls

Keywords